Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Randomized Controlled, Open-label, Multicenter Clinical Study of Pyrotinib Maleate Combined With Trastuzumab,Dalpiciclib, and Letrozole Versus Trastuzumab Combined With Pertuzumab, Docetaxel, and Carboplatin as Neoadjuvant Therapy for Stage II-III HR +/HER2 + Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05638594
• Other study ID #: MUKDEN-09
• Status: Recruiting
• Phase: Phase 2
• Start date: December 20, 2022
• Est. completion date: December 10, 2027

Study information

• Verified date: March 2023
• Source: Shengjing Hospital
• Contact: Nan Niu
• Phone: +8618940256668
• Email: niunannancy[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an investigator-initiated randomized controlled, open-label, multicenter, prospective Phase 2 clinical study. Patients with stage II-III HR +/HER2 + breast cancer were randomly divided into two groups at a ratio of 1:1. The experimental group received pyrotinib combined with trastuzumab, dalpiciclib and letrozole; the control group received trastuzumab combined with pertuzumab, docetaxel and carboplatin. The main study objective was to evaluate the efficacy and safety of neoadjuvant therapy for HR +/HER2 + breast cancer in the two groups.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 236
• Est. completion date: December 10, 2027
• Est. primary completion date: December 10, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Female patients aged 18 -75 ;

2. Willing to receive LHRH agonist therapy (premenopausal patients only);

3. All patients were histopathologically confirmed to be estrogen receptor (ER) -positive and HER2-positive.

4. Treatment-naïve stage II-III patients with tumor stage meeting AJCC version 8 criteria;

5. ECOG score 0-1;

6. Organ function level must meet the following requirements:

(1) bone marrow function • ANC = 1.5 x 109/L ; • PLT = 100 × 109/L • Hb = 90 g/L ; (2) hepatic and renal function • TBIL = 1.5 × ULN; • AL and AST = 3 × ULN (ALT and AST = 5 × ULN in patients with liver metastases); • BUN and Cr = 1.5 × ULN and creatinine clearance = 50 mL/min; (Cockcroft-Gault formula) (3) Echocardiography: LVEF = 50%; (4) 12-lead ECG: QT interval = 480 ms; 7. Able to undergo needle biopsy; 8. Voluntarily join this study to sign informed consent, have good compliance and willing to cooperate with follow-up.

Exclusion Criteria:

1. Received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);

2. Received any other anti-tumor therapy at the same time;

3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer;

4. Stage IV breast cancer;

5. Breast cancer without histopathological diagnosis;

6. Other malignant tumors in the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ;

7. Severe heart, liver and kidney and other vital organ dysfunction;

8. Inability to swallow, chronic diarrhea and intestinal obstruction, there are a variety of factors affecting drug administration and absorption;

9. Participated in other drug clinical trials within 4 weeks before enrollment;

10. Known history of hypersensitivity to the drug components of this protocol; history of immunodeficiency, including positive HIV test, HCV, active viral hepatitis B or other acquired, congenital immunodeficiency diseases, or history of organ transplantation;

11. Had any cardiac disease, including: (1) cardiac arrhythmia requiring medication or clinically significant; (2) myocardial infarction; (3) heart failure; (4) any other cardiac disease judged by the investigator to be inappropriate for participation in this trial;

12. Female patients who are pregnant or lactating, female patients of childbearing potential with a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures throughout the trial;

13. According to the investigator 's judgment, there are concomitant diseases that seriously jeopardize the patient' s safety or affect the patient 's completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection, etc.);

14. Had a documented history of neurological or psychiatric disorders, including epilepsy or dementia.Any other condition that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Pyrotinib
320mg, qd
• Trastuzumab
8 mg/kg first dose, then 6 mg/kg,q3w
• Dalpiciclib
125mg , qd,d1-21, q4w
• Letrozole
2.5mg,qd
• Pertuzumab
840 mg first dose, then 420 mg, q3w
• Docetaxel
75 mg/m2, q3w
• Carboplatin
AUC 6, q3w
• Gonadotropin-releasing hormone agonist
Every 4 weeks for 5 cycles, premenopausal patients only

Locations

Country	Name	City	State
China	Shengjing Hospital of China Medical University	Shenyang	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
Shengjing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Disease-free survival (DFS)	It refers to the length of time from the start of medication after enrollment to the death of the patient because of the recurrence, distant metastasis of the disease, invasive contralateral breast cancer, or any other cause	6 years
Other	Overall survival (OS)	It refers to the length of time from the start of treatment to the death of the patient.	10 years
Primary	Pathologic Complete Response Rate (tpCR: ypT0-is/ypN0)	Proportion of patients without any residual invasive cancer in pathological assessment of hematoxylin and eosin-stained resected breast cancer samples and all ipsilateral lymph node samples following completion of neoadjuvant therapy and surgery	3 years
Secondary	Best overall response	Proportion of patients with tumor response at any time during the study	3 years
Secondary	Breast Pathologic Complete Response Rate (bpCR: ypT0-is)	Proportion of patients without any residual invasive carcinoma in pathological assessment of hematoxylin and eosin stained resected breast cancer samples following completion of neoadjuvant therapy and surgery.	3 years
Secondary	Residual cancer burden (RCB)	RCB score is obtained according to pathological evaluation after completion of neoadjuvant treatment and surgery	3 years